Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026)
Agios Pharmaceuticals (AGIO) reported EBT Margin of 478.31% for Q1 2026, up 55930.0% on a YoY basis from N/an in Q1 2025, and up 12.43% quarter-over-quarter from 546.18% in Q4 2025.
Agios Pharmaceuticals (AGIO) EBT Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals has reported EBT Margin for 14 years, with the latest figure at 478.31% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 55930.0% year-over-year to 478.31%; the trailing twelve-month figure through Mar 2026 stood at 642.35% (down 255243.0% YoY), and the FY2025 full-year result was 765.89%, down 273304.0% from the prior year.
- EBT Margin for Q1 2026 stood at 478.31%, up from 546.18% in the prior quarter.
- The five-year high for EBT Margin was 11167.28% in Q3 2024, with the low at 12073.44% in Q1 2022.
- Historically, EBT Margin has averaged 1146.23% across 5 years, with a median of 1134.03% in 2024.
- Annual changes were most pronounced in 2024 — EBT Margin surged 1240156 bps — and 2025, when it slumped 1197033 bps.
- Agios Pharmaceuticals' EBT Margin stood at 2150.44% in 2022, then soared by 37 bps to 1350.7% in 2023, then rose by 27 bps to 982.28% in 2024, then jumped by 44 bps to 546.18% in 2025, then increased by 12 bps to 478.31% in 2026.
- The last three EBT Margin figures came in at 478.31% (Q1 2026), 546.18% (Q4 2025), and 803.05% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.01 Bn | 2.01 Bn | 19.43 Mn | -478.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -478.31% |
| Dec 31, 2025 | -546.18% |
| Sep 30, 2025 | -803.05% |
| Jun 30, 2025 | -903.60% |
| Mar 31, 2025 | -1,037.61% |
| Dec 31, 2024 | -982.28% |
| Sep 30, 2024 | 11,167.28% |
| Jun 30, 2024 | -1,134.03% |
| Mar 31, 2024 | -1,015.79% |
| Dec 31, 2023 | -1,350.70% |
| Sep 30, 2023 | -1,234.27% |
| Jun 30, 2023 | -1,273.03% |
| Mar 31, 2023 | -1,471.24% |
| Dec 31, 2022 | -2,150.44% |
| Sep 30, 2022 | -2,482.14% |
| Jun 30, 2022 | -1,717.07% |
| Mar 31, 2022 | -12,073.44% |
| Dec 31, 2020 | -191.94% |
| Sep 30, 2020 | -228.13% |
| Jun 30, 2020 | -218.21% |